Blood, Vol. 89 No. 7 (April 1), 1997:
pp. 2298-2302
Treatment of Chronic Graft-Versus-Host Disease With Clofazimine
By
Stephanie J. Lee,
Scott A. Wegner,
Carol J. McGarigle,
Barbara E. Bierer, and
Joseph H. Antin
From the Division of Hematology/Oncology, the Department of Medicine, Brigham and Women's Hospital, Boston; the Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston; and the Department of Medicine, Harvard Medical School, Boston, MA.
 |
ABSTRACT |
Clofazimine (Lamprene) is an antimycobacterial drug that has antiinflammatory activity in a number of chronic autoimmune skin disorders. We report 22 patients treated with clofazimine for chronic graft-versus-host disease (cGVHD). The initial dose was 300 mg orally in a single daily dose for 90 days. After 90 days, the dose was lowered to 100 mg orally each day and the medication continued indefinitely as tolerated. Treatment courses lasted 7 to 835 days and were generally well tolerated. Gastrointestinal side effects occurred in eight of 22 patients (36%) and hyperpigmentation was noted in 12 of 22 patients (55%), which resolved upon decrease or discontinuation of the drug. Over 50% of patients with skin involvement, flexion contractures, or oral manifestations achieved complete or partial responses. Seven of 22 patients (32%) were able to reduce other immunosuppressive medications. Thus, clofazimine is safe and has encouraging efficacy in cGVHD, particularly if sclerodermatous skin, joint contractures, or oral manifestations are present. The mechanism by which clofazimine induces a response is unknown, but might be secondary to suppression of alloreactive T-cell function in cGVHD target organs. Clofazimine deserves further study for the treatment of cGVHD.
| |
INTRODUCTION |
CHRONIC graft-versus-host disease (cGVHD) is a frequent late complication of allogeneic bone marrow transplantation. It affects 50% of long-term transplant survivors,1 and mortality occurs in 20% to 40% of affected patients despite aggressive treatment.2 Chronic GVHD may involve virtually any organ.1,3 Primary therapy for extensive cGVHD typically includes corticosteroids and cyclosporine.4 However, this combination therapy is often unsuccessful in patients with extensive multiorgan involvement.2 Azathioprine is sometimes used as a steroid-sparing agent, but is associated with a higher risk of infections.5 All of these conventional agents are associated with significant therapy-related complications. Because of the toxicity and incomplete response rate of conventional treatment for cGVHD, alternative approaches are needed for patients who cannot tolerate or do not respond to first-line therapy. One such drug is thalidomide, which is beneficial in 20% to 59% of patients,6,7 but often causes sedation and neuropathy and is not commercially available. Case reports exist showing response for other agents, such as penicillamine,8 photopheresis,9 and psoralen and ultraviolet A (PUVA) therapy,10-12 but experience with these modalities is limited.
Clofazimine is an antimycobacterial agent that has been used extensively in the treatment of leprosy and Mycobacterium avium complex since the 1960s.13 Furthermore, it has demonstrated efficacy in the treatment of immune-mediated skin disease such as cutaneous discoid and annular lupus erythematosis,14,15 pyoderma gangrenosum,16-19 and pustular psoriasis.20 The mechanism of clofazimine action in these conditions is unknown, but is thought to reflect functional inhibition of pathogenic T lymphocytes. Although the drug is relatively well tolerated, side effects, when they occur, involve the skin, eyes, and gastrointestinal tract,13,21,22 all major sites of cGVHD involvement. Clofazimine is secreted in sweat, sebum, tears, and saliva, and clofazimine crystals are found precipitated in Peyer's patches, skin, lymph nodes, spleen, and other organs in patients receiving long-term therapy.21,23-25 We hypothesized that clofazimine might have efficacy in cGVHD given its apparent immunomodulatory activity and tissue distribution.
| |
MATERIALS AND METHODS |
Patients treated before August 1992 received clofazimine (Ciba-Geigy Inc, Summit, NJ) off protocol. Patients treated after that date were enrolled on an open-label, phase II trial of clofazimine. The phase II study was approved by the Human Research Committee of the Brigham and Women's Hospital, Boston, MA. All patients received clofazimine, 300 mg in a single oral dose with food for 90 days. After 90 days, the dose of clofazimine was reduced to 100 mg daily. Patients enrolled in the phase II study received clofazimine provided by Ciba-Geigy Inc.
Patients treated on protocol received baseline evaluations including a history and physical examination, complete blood count with differential, complete chemistry panel, and lymphocyte phenotyping panel. When indicated, patients were evaluated by an oral surgeon and ophthalmologist, and flexion contractures, when present, were measured by a physical therapist. Skin, liver, lung, or mucous membrane biopsies were performed as clinically indicated. Physical assessment was repeated every 2 weeks and laboratory studies were repeated every 4 weeks during the study. Lymphocyte phenotyping for T, B, and natural killer cell antigens was performed by direct immunofluorescence using monoclonal antibodies directed against CD3, CD5, CD4, CD8, CD56, CD57, CD16, and CD19. Studies were performed on enrollment in the study, at 3 months, and every several months thereafter, as long as patients remained on study. Patients received pneumocystis and pneumococcal prophylaxis, as well as Ig replacement if sinopulmonary infections occurred in the setting of Ig deficiency. All patients received their primary follow-up care and evaluation for response to clofazimine at the Brigham and Women's Hospital. Therapy was discontinued if patients experienced progressive cGVHD despite clofazimine, intolerable side effects, or reached a plateau without further improvement. Therapy could be reinitiated if cGVHD recrudesced; however, only an aggregate best response for all courses is reported. Two patients received their initial bone marrow transplants at other hospitals; these patients were treated with adoptive immunotherapy26 and for their subsequent cGVHD at the Brigham and Women's Hospital.
Response rates were determined by review of medical records. Complete organ responses were defined as resolution of skin, joint, oral, pulmonary, or ocular manifestations. Partial responses were defined as a greater than 50% response in organ involvement, but less than complete response. Stable disease was defined as stable organ involvement despite the tapering of other immunosuppressive agents by at least 50% of the dosage. No response referred to progressive worsening of cGVHD or stability of cGVHD, but inability to taper other medications. When judging overall response, patients experiencing complete resolution of all cGVHD manifestations were considered complete responders, patients with partial response of any organ were classified as partial responders, and those without any organ response or stable manifestations were nonresponders.
| |
RESULTS |
Twenty-two patients were studied between November 1990 and December 1995. Nine of the 22 patients (41%) were treated off protocol and 13 of 22 (59%) received clofazimine on protocol. The two treatment groups did not differ with regards to demographics, dose, and schedule of drug administered, or response rate, and results were pooled. Patient characteristics are shown in Table 1. The average age of patients was 36 years (range, 24 to 54 years) and 77% of patients were transplanted for hematologic malignancies. Nineteen of 22 patients (86%) received cyclophosphamide and total body irradiation (1,400 rads) ± cytosine arabinoside as preparation for transplantation as previously described.27 Sixteen patients (73%) underwent related donor transplantation of whom 3 (14%) developed cGVHD following adoptive immunotherapy; 6 patients (27%) were transplanted from unrelated donors.
Prognostic factors and onset of cGVHD are shown in Table 2. Diagnosis of cGVHD was based either on pathologic documentation of organ involvement or clinical features. Twelve patients (56%) had documented acute grade II to IV GVHD; 16 of 22 patients (73%) had quiescent onset cGVHD and 3 of 22 (14%) had a progressive presentation. Three patients (14%) presented with de novo cGVHD. At initiation of clofazimine therapy, 77% of patients were receiving cyclosporine and steroids, 9% steroids alone, 5% cyclosporine alone, and 9% no other therapy. At the time of clofazimine discontinuation, 55% of patients were receiving cyclosporine and steroids, 18% steroids alone, 5% cyclosporine alone, and 23% no immunosuppression. Follow-up information was collected through June 1, 1996; a total of 6,895 patient-days on treatment had elapsed with an average treatment course lasting 313 days. One patient received three separate courses of clofazimine, but attained the same response for all courses; she is reported only once. Six patients remain on clofazimine therapy after 172 to 835 days. One patient discontinued medication prematurely because of side effects. He restarted medication 6 weeks later and attained a stable response (overall no response) without side effects and remains on therapy.
Response rates for different organ systems are shown in Table 3. The numbers of patients considered evaluable for organ involvement are lower than expected, as only active, severe manifestations for which clofazimine was initiated were evaluable by notations in the medical record. At least 50% of patients treated for skin, joint, or mouth involvement achieved partial or complete responses in those organs. Nine of 16 patients (56%) treated for skin cGVHD achieved partial responses; we did not observe a different response rate between clinically sclerodermatous and lichenoid involvement. Three of six (50%) patients treated for oral involvement also partially responded. Seven of 11 (63%) patients had improvement in joint mobility; 4 of these patients (36%) attained complete remissions with release of contractures. Only one partial response was seen in patients treated for pulmonary or ocular symptoms, although the evaluable patient population was small (n = 5).
Overall, 12 of 22 (55%) patients achieved a partial response. Patients with both limited disease (4 of 6 [66%]) and with extensive disease (8 of 16 [50%]) responded. No overall complete responses were observed. Five patients (23%) decreased the dosages of other immunosuppressive medications by at least 50%, in addition to achieving partial organ responses. Two additional patients (9%) also decreased other immunosuppressive medications by 50%, although their symptoms did not improve; these two patients were classified as overall nonresponders.
Sequential lymphocyte phenotyping studies did not show any significant trends during or after treatment with clofazimine (data not shown). White blood cell count, platelet count, hematocrit, and serum bilirubin also did not change significantly (data not shown). Infections were neither quantitatively nor qualitatively increased above baseline during or after treatment with clofazimine (data not shown).
Side effects were generally mild. Eight patients (36%) had abdominal symptoms, consisting of nausea, vomiting, cramps, constipation, or diarrhea. These symptoms were considered intolerable in 4 of 22 (18%) patients and resulted in discontinuation of clofazimine. Twelve patients (55%) developed red-brown hyperpigmentation of the skin and conjunctiva, but none requested withdrawal from the study. No ophthalmologic complications were observed. All side effects were reversible upon stopping clofazimine treatment.
Six patients (27%) died between 7 to 482 days after starting clofazimine; 2 from infection (1 on therapy at 252 days; 1 off therapy for 402 days after 20 days of clofazimine), 1 from bronchiolitis obliterans (on therapy at 7 days), 1 from leukemic relapse (off therapy for 277 days after receiving 233 days of clofazimine), 1 from an ill-defined neuromuscular process (off therapy for 239 days after receiving 104 days of clofazimine), and 1 after electing to discontinue dialysis (87 days after starting clofazimine, but off therapy). Clofazimine was not believed to be contributory to these deaths.
| |
DISCUSSION |
Clofazimine has been used extensively for the treatment of leprosy and Mycobacterium avium complex and reported to be useful in several immunologically mediated skin disorders. In an open trial, 10 patients with pyoderma gangrenosum were treated with clofazimine with achievement of complete remission in 7 and partial responses in 2.18 Multiple open label trials have shown clofazimine to be effective in the treatment of cutaneous lupus lesions14,28 of pyoderma gangrenosum and its variants16-19 and of psoriasis.20
The mechanism of action of clofazimine is unclear, although several studies have suggested that it has immunomodulatory effects.29 Documented effects of clofazimine, in vitro, include an inhibition of lymphocyte responsiveness to mitogen stimulation,30 possibly due to increased release of lysophospholipids,31 decreased neutrophil motility,30 increased spontaneous production of reactive oxidants by mononuclear leukocytes,29 increased synthesis of prostaglandin E2,32 and increased clearance and degradation of circulating immune complexes by macrophages in vitro.33
A number of reports have demonstrated effects of clofazimine that might predict increased immune activity. In vitro studies of peripheral blood monocytes from healthy volunteers have demonstrated increased major histocompatibility complex (MHC) class II expression following incubation with clofazimine,34 increased oxygen uptake during phagocytosis in neutrophils derived from patients with pyoderma gangrenosum during clofazimine therapy,17 and decreased suppressor T-cell activity in mycobacteria-infected mice during clofazimine treatment.35 In our study, we observed no consistent changes in the percentages or absolute numbers of CD4+ helper T cells, CD8+ cytotoxic/suppressor cells, or CD16+ natural killer cells. Serial lymphocyte functional studies were not performed.
The majority of in vitro studies used concentrations of clofazimine, which are achievable in vivo, as a 300 mg daily dose results in predicted serum levels of 1.0 µg/mL.36 The half-life of clofazimine in man is approximately 70 days due to its highly lipophilic nature.13,23,37 However, in vivo efficacy of clofazimine may be related to high local tissue levels of the drug. Crystals of clofazimine have been shown by electron microscopy to be present in skin, Peyer's patches, and the reticuloendothelial system for a prolonged time following therapy. Because these sites are target organs for cGVHD, increases in local concentration may accentuate the immunosuppressive effects of clofazimine at these sites.
Long-term complications from prolonged use of clofazimine in humans have not been demonstrated38 and eight of our patients have been treated for more than a year. In other settings, commonly reported side effects include skin discoloration, gastrointestinal symptoms (nausea, cramping, diarrhea, constipation), and ocular symptoms, which are reversible upon discontinuation of the drug.13,21,22,39,40 We observed both gastrointestinal and cutaneous side effects. We did not observe any ocular complications of clofazimine therapy.
In summary, clofazimine is safe and has encouraging efficacy in the treatment of cGVHD. The results in patients with sclerodermatous skin, joint, or oral involvement were particularly encouraging. The lack of observed infectious complications differentiates clofazimine from first-line treatments for cGVHD and is an attractive feature of the drug, given the already markedly impaired immune function in patients with this disease. Furthermore, if clofazimine allows reduction in cyclosporine and corticosteroid requirements, it may reduce the risk of complications due to iatrogenic immunosuppression. Given its relative lack of toxicity, we suggest that clofazimine deserves further study in the treatment of cGVHD.
| |
FOOTNOTES |
Submitted August 2, 1996;
accepted November 4, 1996.
Supported in part by National Institutes of Health Grants No. CA 58661 and CA 39542.
Address reprint requests to Joseph H. Antin, MD, Division of Hematology/Oncology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
We thank the nurses, housestaff, fellows, and our colleagues at the Brigham and Women's Hosptial for the care of these patients.
| |
REFERENCES |
1.
Atkinson K:
Chronic graft-versus-host disease.
Bone Marrow Transplant
5:69,
1990[Medline]
[Order article via Infotrieve]
2.
Wingard JR,
Piantadosi S,
Vogelsang GB,
Farmer ER,
Jabs DA,
Levin LS,
Beschorner WE,
Cahill RA,
Miller DF,
Harrison D,
Saral R,
Santos GW:
Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.
Blood
74:1428,
1989[Abstract/Free Full Text]
3.
Shulman HM,
Sullivan KM,
Weiden PL,
McDonald GB,
Striker GE,
Sale GE,
Hackman R,
Tsoi M-S,
Storb R,
Thomas ED:
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study in 20 Seattle patients.
Am J Med
69:204,
1980[Medline]
[Order article via Infotrieve]
4.
Sullivan KM,
Witherspoon RP,
Storb R,
Deeg HJ,
Dahlberg S,
Sanders JE,
Appelbaum FR,
Doney KC,
Weiden P,
Anasetti C,
Loughran TP,
Hill R,
Shields A,
Yee G,
Shulman H,
Nims J,
Strom S,
Thomas ED:
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
Blood
72:555,
1988[Abstract/Free Full Text]
5.
Sullivan KM,
Witherspoon RP,
Storb R,
Weiden P,
Flournoy N,
Dahlberg S,
Deeg HJ,
Sanders JE,
Doney KC,
Appelbaum FR,
McGuffin R,
McDonald GB,
Meyers J,
Schubert MM,
Gauvreau J,
Shulman HM,
Sale GE,
Anasetti C,
Loughran TP,
Strom S,
Nims J,
Thomas ED:
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
Blood
72:546,
1988[Abstract/Free Full Text]
6.
Vogelsang GB,
Farmer ER,
Hess AD,
Altamonte V,
Beschorner WE,
Jabs DA,
Corio RL,
Levin LS,
Colvin OM,
Wingard JR,
Santos GW:
Thalidomide for the treatment of chronic graft-versus-host disease.
N Engl J Med
326:1055,
1992[Abstract]
7.
Parker PM,
Chao N,
Nademanee A,
O'Donnell MR,
Schmidt GM,
Snyder DS,
Stein AS,
Smith EP,
Molina A,
Stepan DE,
Kashyap A,
Planas I,
Spielberger R,
Somlo G,
Margolin K,
Zwingenberger K,
Wilsman K,
Negrin RS,
Long GD,
Niland JC,
Blume KG,
Forman SJ:
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Blood
86:3604,
1995[Abstract/Free Full Text]
8.
Summerfield GP,
Bellingham AJ,
Bunch C,
Woodrow JC:
Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine.
Clin Lab Haematol
5:313,
1983[Medline]
[Order article via Infotrieve]
9.
Owsianowski M,
Gollnick H,
Siegert W,
Schwerdtfeger R,
Orfanos CE:
Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis.
Bone Marrow Transplant
14:845,
1994[Medline]
[Order article via Infotrieve]
10.
Kapoor N,
Pelligrini AE,
Copelan EA,
Cunningham I,
Avalos BR,
Klein JL,
Tutschka PJ:
Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: Preliminary experience in standard treatment resistant patients.
Semin Hematol
29:108,
1992[Medline]
[Order article via Infotrieve]
11.
Eppinger T,
Ehninger G,
Steinert M,
Niethammer D,
Dopfer R:
8-methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease.
Transplantation
50:807,
1990[Medline]
[Order article via Infotrieve]
12.
Vogelsang GB,
Wolff D,
Altomonte V,
Farmer E,
Morison WL,
Corio R,
Horn T:
Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
Bone Marrow Transplant
17:1061,
1996[Medline]
[Order article via Infotrieve]
13.
Holdiness MR:
Clinical pharmacokinetics of clofazimine. A review.
Clin Pharmacol
16:74,
1989
14.
Mackey JP,
Barnes J:
Clofazimine in the treatment of discoid lupus erythematosus.
Br J Dermatol
91:93,
1974[Medline]
[Order article via Infotrieve]
15.
Crovato F,
Levi L:
Clofazimine in the treatment of annular lupus erythematosus.
Arch Dermatol
117:249,
1981
16.
Michaelsson G,
Molin L,
Ohman S,
Gip L,
Lindstrom B,
Skogh M,
Trolin I:
Clofazimine. A new agent for the treatment of pyoderma gangrenosum.
Arch Dermatol
112:344,
1976[Abstract/Free Full Text]
17.
Brandt L,
Gartner I,
Nilsson PG,
Olofsson T:
Pyoderma gangrenosum associated with regional enteritis.
Acta Med Scand
201:141,
1977[Medline]
[Order article via Infotrieve]
18.
Thomsen C,
Rothenborg HW:
Clofazimine in the treatment of pyoderma gangrenosum.
Arch Dermatol
115:851,
1979[Abstract/Free Full Text]
19.
Mensing H:
Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum).
Dermatologica
177:232,
1988[Medline]
[Order article via Infotrieve]
20.
Chuaprapaisilp T,
Piamphongsant T:
Treatment of pustular psoriasis with clofazimine.
Br J Dermatol
99:303,
1978[Medline]
[Order article via Infotrieve]
21.
Yawalkar SJ,
Vischer W:
Lamprene (Clofazimine) in leprosy.
Lepr Rev
50:135,
1979[Medline]
[Order article via Infotrieve]
22.
Moore VJ:
A review of the side-effects experienced by patients taking clofazimine.
Lepr Rev
54:327,
1983[Medline]
[Order article via Infotrieve]
23.
Mansfield RE:
Tissue concentrations of clofazimine (B663) in man.
Am J Trop Med Hyg
23:1116,
1974
24.
Hudson V,
Cox F,
Taylor L,
Guill M,
Wray B,
Steele J:
Pulmonary clofazimine crystals in a child with acquired immunodeficiency syndrome and disseminated mycobacterium avium-intracellulare infection.
Pediatr Infect Dis J
7:880,
1988[Medline]
[Order article via Infotrieve]
25.
Belaube P,
Devaux J,
Pizzi M,
Boutboul R,
Privat Y:
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene) in the treatment of prurigo nodularis.
Int J Lepr
51:328,
1983
26.
Porter DL,
Roth MS,
McGarigle C,
Ferrara JLM,
Antin JH:
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
N Engl J Med
330:100,
1994[Abstract/Free Full Text]
27.
Mitus AJ,
Miller KB,
Schenkein DP,
Ryan HF,
Parsons SK,
Wheeler C,
Antin JH:
Improved survival for patients with acute myelogenous leukemia.
J Clin Oncol
13:560,
1995[Abstract/Free Full Text]
28.
Zeis BM,
Schulz EJ,
Anderson R,
Kleeberg HH:
Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine.
S Afr Med J
75:161,
1989[Medline]
[Order article via Infotrieve]
29.
Anderson R,
Zeis BM,
Anderson IF:
Clofazimine-mediated enhancement of reactive oxidant production by human phagocytes as a possible therapeutic mechanism.
Dermatologica
176:234,
1988[Medline]
[Order article via Infotrieve]
30.
van Rensburg CEJ,
Gatner EMS,
Imkamp FMJH,
Anderson R:
Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy.
Antimicrob Agents Chemother
21:693,
1982[Abstract/Free Full Text]
31.
Anderson R,
Smit MJ:
Clofazimine and B669 inhibit the proliferative responses and Na+, K+-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism.
Biochem Pharmacol
46:2029,
1993[Medline]
[Order article via Infotrieve]
32.
Anderson R:
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro.
Antimicrob Agents Chemother
27:257,
1985[Abstract/Free Full Text]
33.
Sarracent J,
Finlay CM:
Phagocytosis and intracellular degradation of 125I-labelled immune complexes by clofazimine treated macrophage cultures.
Clin Exp Immunol
48:268,
1982[Medline]
[Order article via Infotrieve]
34.
Wadee AA,
Kuschke RH,
Dooms TG:
The inhibitory effects of Mycobacterium tuberculosis on MHC class II expression by monocytes activated with riminophenazines and phagocyte stimulants.
Clin Exp Immunol
100:434,
1995[Medline]
[Order article via Infotrieve]
35.
Watson S,
Auclair LK,
Collins FM:
The effect of combined chemotherapy on suppressor T-cell activity in Mycobacterium simiae-infected mice.
Immunology
43:459,
1981[Medline]
[Order article via Infotrieve]
36.
Banerjee DK,
Ellard GA,
Gammon PT,
Waters MFR:
Some observations on the pharmacology of clofazimine (B663).
Am J Trop Med Hyg
23:1110,
1974
37.
Levy L:
Pharmacologic studies of clofazimine.
Am J Trop Med Hyg
23:1097,
1974
38.
Hastings RC,
Jacobson RR,
Trautman JR:
Long-term clinical toxicity studies with clofazimine (B663) in leprosy.
Int J Lepr
44:287,
1976
39.
Craythorn JM,
Swartz M,
Creel DJ:
Clofazimine-induced bull's-eye retinopathy.
Retina
6:50,
1986[Medline]
[Order article via Infotrieve]
40.
Ohman L,
Wahlberg I:
Ocular side-effects of clofazimine.
Lancet
2:933,
1975[Medline]
[Order article via Infotrieve]
Abstract
Introduction
Abstract
